Zhitong Finance App News, Hehuang Pharmaceutical (00013.HK) announced that the marketing application for fanregratinib (HMPL-453) has been conditionally approved by the China National Drug Administration (China Drug Administration) to treat adult patients with advanced, metastatic, or intrahepatic cholangiocarcinoma who have received systematic treatment in the past and have fibroblast growth factor receptor (FGFR) 2 fusion or rearrangement. Vanreglatinib will be sold in the Chinese market under the trade name Ailinda® (English trademark: ATLED®).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.